I took lecithin in liquid and in granular form for 25 years. (anyone remember the tin bottles?) Looking back, I should not have stopped taking it. It fell out of favor with the nutritional Avant-guard, perhaps a lesson for us today.
@Joseph , I recommend you run any paper you think is interesting through this prompt on Gemini Pro before you take it too seriously. See the prompt here: Using AI for Health and Longevity and Research - Your Favorite Prompts - #87 by RapAdmin
I run dozens of papers through this “Filter” before I bother posting one that is good enough that I think most people may want to read about it. Most papers are not very good papers, have low rankings, and little actionable information. So I don’t waste your time with them.
This paper you’ve posted has lots of problems… very low impact / low quality rating and ranking, lots of errors… probably not worth your time reading.
Lecithin, LCAT, and the Lipid Paradox
Source: Lecithin and cardiovascular health: a comprehensive review (2024)
The LCAT Paradox: Lipid Remodeling Potential Marred by a “TMAO Blindspot”
This narrative review, published in The Egyptian Heart Journal (Springer), attempts to rehabilitate Lecithin—a common phospholipid supplement—as a serious tool for cardiovascular risk reduction. The authors argue that Lecithin does more than simply emulsify fats; it purportedly upregulates Lecithin Cholesterol Acyltransferase (LCAT), a critical enzyme responsible for the maturation of High-Density Lipoprotein (HDL) and Reverse Cholesterol Transport (RCT). The core thesis is that by feeding the LCAT pathway, Lecithin accelerates the removal of cholesterol from the periphery to the liver, thereby reducing atherosclerotic plaque burden.
However, The “Big Idea” here is overshadowed by a glaring omission. While the paper aggressively promotes the pro-RCT mechanisms of Lecithin, it largely ignores the “TMAO (Trimethylamine N-oxide) Blindspot.” Modern longevity science recognizes that dietary phosphatidylcholine (the active component of Lecithin) is a primary substrate for gut bacteria to produce TMA, which the liver oxidizes into TMAO—a known pro-inflammatory and pro-thrombotic metabolite.
The impact score of this journal is CiteScore 1.4 (Q3), evaluated against a typical high-end range of 10–60+ (e.g., Nature, Cell), therefore this is a Low impact journal. It effectively highlights the biological plausibility of LCAT activation but fails to reconcile this with the complex, often paradoxical clinical data regarding LCAT overexpression and actual mortality outcomes.
Mechanistic Deep Dive
The authors posit that Lecithin is not just a nutrient but a signaling modulator. By increasing substrate availability for LCAT, Lecithin drives the conversion of “nascent” (discoidal) HDL into “mature” (spherical) HDL. Theoretically, this prevents the accumulation of small, dense LDL (sdLDL)—the most atherogenic lipoprotein subclass.
The Longevity Critique: The review commits a “mechanistic fallacy.” It assumes that any increase in RCT flux equals reduced mortality. However, genetic studies (Mendelian Randomization) have shown that raising HDL-C or LCAT activity does not always reduce heart attacks. Furthermore, the review fails to address the Microbiome Axis. For a biohacker, taking Lecithin without knowing your gut flora’s capacity to produce TMAO is risky. You might improve your lipid profile while simultaneously increasing vascular inflammation and platelet reactivity via TMAO.
Novelty & Limitations
- Novelty: Low. It consolidates known biochemistry but offers no new clinical evidence. Its value lies in summarizing the “LCAT Paradox”—the confusing finding where high LCAT sometimes correlates with worseoutcomes in specific disease states (e.g., nephropathy), which the authors acknowledge but do not fully resolve.
-
Critical Limitations:
- No TMAO Risk Assessment: Fails to discuss the pro-atherogenic conversion of choline/phosphatidylcholine to TMAO.
- Surrogate Endpoint Bias: Relies on LDL/HDL ratios rather than hard outcome data (heart attack/stroke/death).
- Translational Gap: Extrapolates heavily from rodent/rabbit models where lipid metabolism differs significantly from humans (mice are HDL-dominant; humans are LDL-dominant).
Part 3: Claims & Verification
Claim 1: Lecithin supplementation significantly reduces LDL cholesterol and total cholesterol.
- Verdict: Verified (Context Dependent)
- Hierarchy: Level B (Small RCTs)
- Analysis: Historical and small-scale human trials support this. A study on hypercholesterolemic patients showed significant reductions, but modern statin therapies are vastly more potent. The effect size in the review (sometimes cited >40%) is likely an outlier compared to general population data.
- Evidence: Influence of Soy Lecithin Administration on Hypercholesterolemia (2010)
- Confidence: [Medium]
Claim 2: Increasing LCAT activity reduces atherosclerosis risk.
- Verdict: Controversial / Mixed Evidence
- Hierarchy: Level C/D (Observational/Mechanistic)
- Analysis: This is the “LCAT Paradox.” While LCAT is essential for HDL maturation, genetic overexpression in animals yields conflicting results (sometimes protective, sometimes neutral). Human genetic LCAT deficiency causes corneal and renal issues but does not always lead to massive premature atherosclerosis as expected.
- Evidence: Role of LCAT in atherosclerosis (2016)
- Confidence: [Low] - The biological role is clear, but the therapeutic benefit of forcing this pathway is unproven.
Claim 3: Lecithin improves cognitive function via Choline.
- Verdict: Weak / Inconclusive
- Hierarchy: Level A/B (Systematic Reviews)
- Analysis: While Choline is a precursor to acetylcholine, systematic reviews (e.g., Cochrane) generally find no robust benefit of Lecithin for treating dementia or cognitive impairment in established disease, though it may support general neuronal health.
- Evidence: Lecithin for dementia and cognitive impairment (2003)
- Confidence: [Low]